D
Donald L. Trump
Researcher at Roswell Park Cancer Institute
Publications - 272
Citations - 22973
Donald L. Trump is an academic researcher from Roswell Park Cancer Institute. The author has contributed to research in topics: Prostate cancer & Calcitriol. The author has an hindex of 70, co-authored 272 publications receiving 21805 citations. Previous affiliations of Donald L. Trump include National Institutes of Health & University of Wisconsin-Madison.
Papers
More filters
Journal ArticleDOI
Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer
H. Barton Grossman,Ronald B. Natale,Catherine M. Tangen,V. O. Speights,Nicholas J. Vogelzang,Donald L. Trump,Ralph W deVere White,Michael F. Sarosdy,David P. Wood,Derek Raghavan,E. David Crawford +10 more
TL;DR: Using neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin followed by radical cystectomy increases the likelihood of eliminating residual cancer in the Cystectomy specimen and is associated with improved survival among patients with locally advanced bladder cancer.
Journal ArticleDOI
Vitamin D signalling pathways in cancer: potential for anticancer therapeutics
TL;DR: The epidemiological, preclinical and clinical studies that support the development of 1α,25(OH)2D3 and vitamin D analogues as preventative and therapeutic anticancer agents are outlined.
Journal ArticleDOI
Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer.
Edward M. Messing,Judith Manola,Michael F. Sarosdy,George Wilding,E. D. Crawford,Donald L. Trump +5 more
TL;DR: Immediate antiandrogen therapy after radical prostatectomy and pelvic lymphadenectomy improves survival and reduces the risk of recurrence in patients with node-positive prostate cancer.
Journal ArticleDOI
Hypersensitivity reactions from taxol.
Raymond B. Weiss,Ross C. Donehower,Peter H. Wiernik,T Ohnuma,R J Gralla,Donald L. Trump,J R Baker,D. A. Van Echo,D. D. Von Hoff,Brian Leyland-Jones +9 more
TL;DR: Hypersensitivity reactions to taxol have been one of the toxicities observed with administration of this drug and guidelines are provided to prevent or minimize such toxicity and treat reactions if they still occur.
Journal ArticleDOI
Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group
Glenn J. Bubley,Michael A. Carducci,William L. Dahut,Nancy A. Dawson,Danai Daliani,Mario A. Eisenberger,William D. Figg,Boris Freidlin,Susan Halabi,Gary R. Hudes,Maha Hussain,Richard Kaplan,Charles E. Myers,William Oh,Daniel P. Petrylak,Eddie Reed,Bruce J. Roth,Oliver Sartor,Howard I. Scher,Jonathan W. Simons,V. J. Sinibaldi,Eric J. Small,Matthew R. Smith,Donald L. Trump,Robin T. Vollmer,George Wilding +25 more
TL;DR: The purpose of determining the number of patients whose PSA level drops in a phase II trial of AIPC is to guide the selection of agents for further testing and phase III trials and developed practical guidelines for using PSA as a measurement of outcome.